Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult...
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Allergan assesses brazikumab in two clinical programmes for IBD
- AstraZeneca reports negative top-line results from TULIP 1 trial
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
Okairos’ hepatitis C vaccine fails to show effectiveness in trial
The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine.
J&J’s Phase IIb HIV prevention trial reaches full enrolment
Johnson & Johnson (J&J) has completed enrolment procedures for the Phase IIb Imbokodo clinical trial of an investigational, mosaic-based vaccine regimen to prevent HIV-1 infection.
Pfizer’s Lyrica fails to meet primary endpoint in Phase III trial
Pfizer has reported top-line data from a Phase III clinical trial of Lyrica (pregabalin) as an adjunctive therapy in epilepsy patients suffering from primary generalised tonic-clonic (PGTC) seizures.
Array’s triple combination trial meets goals in colorectal cancer
Array BioPharma has reported positive data from the interim analysis of the Phase III BEACON CRC clinical study being conducted to assess Braftovi (encorafenib), Mektovi (binimetinib) and Erbitux (cetuximab) in metastatic colorectal cancer (mCRC).
AstraZeneca’s Novel START trial shows Symbicort therapy effectiveness
AstraZeneca's Novel Symbicort Turbuhaler Asthma Reliever Therapy (START) trial has demonstrated the effectiveness of its Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.
NIH’s LATITUDE trial to study long-acting HIV regimen
A new National Institutes of Health (NIH)-funded clinical trial has been started to assess a long-acting antiretroviral therapy (ART) for the treatment of people living with HIV.
Daiichi Sankyo-AstraZeneca’s breast cancer therapy clears trial
Daiichi Sankyo and AstraZeneca have reported positive findings from the Phase II DESTINY-Breast01 clinical trial of trastuzumab deruxtecan (DS-8201).
Merck’s V114 yields positive data in pneumococcal disease
Merck Sharp & Dohme has reported positive results from the Phase II clinical trial of its investigational 15-valent pneumococcal conjugate vaccine, V114.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.